智飞生物9月24日获融资买入6616.36万元，融资余额15.87亿元

Core Insights - On September 24, Zhifei Biological experienced a 0.61% increase in stock price with a trading volume of 446 million yuan [1] - The company reported a net financing purchase of 3.29 million yuan on the same day, with a total financing and securities balance of 1.59 billion yuan [1] Financing Summary - On September 24, Zhifei Biological had a financing purchase of 66.16 million yuan, with a current financing balance of 1.58 billion yuan, representing 3.11% of its market capitalization [1] - The financing balance is above the 60th percentile of the past year, indicating a high level of financing activity [1] Securities Lending Summary - On September 24, Zhifei Biological repaid 3,500 shares in securities lending and sold 4,400 shares, amounting to a selling value of 93,700 yuan [1] - The remaining securities lending balance was 167,000 shares, with a total value of 3.56 million yuan, exceeding the 70th percentile of the past year [1] Company Overview - Zhifei Biological, established on July 20, 1995, and listed on September 28, 2010, is based in Chongqing and specializes in the research, production, and sales of vaccines and biological products [1] - The company's revenue composition includes 88.84% from agency products, 10.15% from self-developed products, and 1.00% from other sources [1] Shareholder and Financial Performance - As of August 20, the number of shareholders for Zhifei Biological was 139,500, a decrease of 0.28%, while the average circulating shares per person increased by 0.28% to 10,139 shares [2] - For the first half of 2025, the company reported a revenue of 4.919 billion yuan, a year-on-year decrease of 73.06%, and a net profit of -597 million yuan, a decrease of 126.72% [2] - Cumulatively, the company has distributed 7.318 billion yuan in dividends since its A-share listing, with 3.194 billion yuan in the last three years [2] Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the third-largest circulating shareholder with 36.35 million shares, a decrease of 10.59 million shares from the previous period [2] - E Fund's ChiNext ETF and Huatai-PB's CSI 300 ETF were among the top shareholders, with varying changes in their holdings [2]